combivir has been researched along with aplaviroc in 1 studies
| Studies (combivir) | Trials (combivir) | Recent Studies (post-2010) (combivir) | Studies (aplaviroc) | Trials (aplaviroc) | Recent Studies (post-2010) (aplaviroc) |
|---|---|---|---|---|---|
| 122 | 32 | 59 | 38 | 8 | 8 |
| Protein | Taxonomy | combivir (IC50) | aplaviroc (IC50) |
|---|---|---|---|
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amrine-Madsen, H; Demarest, JF; Irlbeck, DM; Kitrinos, KM | 1 |
1 trial(s) available for combivir and aplaviroc
| Article | Year |
|---|---|
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Topics: Anti-HIV Agents; Benzoates; Diketopiperazines; Drug Combinations; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Lamivudine; Phylogeny; Piperazines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Failure; Tropism; Zidovudine | 2009 |